Loading…
German mRNA biotech that co-developed the Pfizer-BioNTech COVID vaccine, now focused on mRNA and antibody cancer therapies.
German mRNA biotech that co-developed the Pfizer-BioNTech COVID vaccine, now focused on mRNA and antibody cancer therapies.
Most revenue still comes from the COVID-19 vaccine Comirnaty, which Pfizer sells in most markets and the two share the profit on, while BioNTech sells it itself in Germany and Turkey. Its cancer drugs are not yet approved, and in 2025 it agreed to co-develop an antibody cancer drug with Bristol Myers Squibb.
Moat: narrow (IP / patents, process know-how). Pioneering mRNA platform IP and manufacturing scale, though pipeline value remains largely unproven outside COVID.
Headquarters: Mainz, Germany · Founded: 2008 · Employees: 7,807
Size BioNTech SE Sponsored ADR (BNTX) is a United States Health Care company (Biotechnology) with a market value of $22.8B, the 455th largest of 3,117 United States companies the cockpit tracks. Shares closed at $87.51 on 6 Nov 2026.
Performance Over six months the shares fell 7.0%, against +15.5% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue fell 1.1% over the last twelve months (peer median +20.8%); the operating margin is -37.6% (peer median 24.6%).
Valuation It trades at 2.0× enterprise value to sales against a peer median of 8.0× (cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +43%, so the hurdle is -37 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 35.5 points below its cost of capital (11.2% WACC).
Short interest Short interest is 0.9% of the free float (15 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $3.09B | $3.24B | $2.98B | $4.13B | $18.2B |
| Revenue growth | — | +9% | -28% | -77% | — |
| Gross profit | $1.97B | $2.51B | $2.39B | $3.51B | $18.0B |
| EBITDA | -$373M | -$301M | -$374M | $1.18B | $16.1B |
| Net income | -$1.97B | -$1.28B | -$720M | $1.01B | $9.92B |
| Free cash flow | $480M | $317M | -$265M | $5.54B | $13.9B |
| Capital expenditure | $301M | $845M | $489M | $763M | $382M |
| Total debt | $361M | $314M | $263M | $242M | $226M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| BioNTech SE Sponsored ADR BNTX | $22.8B | -7% | -1% | -38% | 2.0× | 5.7% |
| Moderna MRNA | $101B | +43% | -28% | -149% | 43.8× | n/a |
| Pfizer PFE | $168B | +14% | +1% | 26% | 3.4× | -4.3% |
| Roche RO.SW | $385B | +22% | -1% | 31% | 5.6× | 0.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BNTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.9% | +5.2% | 6th lowest of 21 |
| 6-month return | -7.0% | +15.5% | 3rd lowest of 21 |
| Distance from 52-week high | -29.4% | -16.2% | 4th lowest of 21 |
| Revenue growth (TTM) | -1.1% | +20.8% | 3rd lowest of 19 |
| Operating margin | -37.6% | 24.6% | 2nd lowest of 19 |
| EV / Sales | 2.0× | 8.0× | cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 5.7% | 9.6% | 5th least demanding of 16 |
| Growth delivered (Del g) | +42.6% | +16.5% | highest of 16 |
| Hurdle (Req g minus delivered) | -36.9 pp | -8.4 pp | least demanding of 16 |
| ROIC minus cost of capital | -35.5 pp | +1.6 pp | 4th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| BioNTech SE Sponsored ADR BNTX | United States | $22.8B | -7% | -1% | -38% | 2.0× | 5.7% | +42.6% |
| United Therapeutics UTHR | United States | $24.1B | -1% | +2% | 44% | 6.9× | -0.4% | +16.5% |
| Wuxi Bio 2269.HK | Hong Kong | $25.0B | +43% | +22% | 32% | 7.3× | 21.8% | +30.2% |
| Neurocrine Biosciences NBIX | United States | $16.7B | +8% | +38% | 25% | 4.4× | -1.7% | +22.3% |
| Genmab A/S GMAB.CO | Denmark | $32.1B | +115% | +14% | 32% | 9.0× | 11.6% | +19.5% |
| Celltrion 068270.KS | South Korea | $34.3B | +10% | +40% | 32% | 8.6× | 8.3% | +17.6% |
| BridgeBio Pharma BBIO | United States | $14.5B | +10% | +167% | -37% | 18.3× | n/a | n/a |
| Summit Therapeutics SMMT | United States | $13.1B | -10% | n/a | n/a | n/a | n/a | n/a |
| Elanco Animal Health ELAN | United States | $12.9B | +9% | +12% | 7% | 3.2× | 34.8% | +7.6% |
| Cspc Pharma 1093.HK | Hong Kong | $12.4B | +5% | +25% | 28% | 2.2× | -10.3% | +0.1% |
| Halozyme Therapeutics HALO | United States | $11.8B | +62% | +41% | 57% | 8.2× | 2.5% | +39.2% |
| Natera NTRA | United States | $44.8B | +60% | +38% | -11% | 16.2× | n/a | n/a |
| Iqvia IQV | United States | $44.8B | +52% | +9% | 14% | 3.4× | 17.3% | +7.5% |
| Bio-Techne TECH | United States | $11.4B | +51% | 0% | 22% | 9.4× | 31.3% | +5.5% |
| Kymera Therapeutics KYMR | United States | $11.2B | +53% | +134% | -396% | 101.2× | n/a | n/a |
| BioMarin Pharmaceutical BMRN | United States | $10.9B | +4% | +20% | 19% | 3.9× | 6.5% | +12.0% |
| Sichuan Kelun Pharmaceutical 002422.SZ | China | $10.8B | +30% | 0% | 9% | 3.9× | 7.2% | +2.3% |
| ALTEOGEN 196170.KS | South Korea | $10.3B | -46% | +61% | 53% | 43.0× | 29.8% | +38.5% |
| Vaxcyte PCVX | United States | $10.1B | +21% | n/a | n/a | n/a | n/a | n/a |
| Samsung Biologics 207940.KS | South Korea | $53.7B | +3% | -20% | 43% | 16.7× | 9.6% | +31.4% |
| Lonza LONN.SW | Switzerland | $55.4B | +39% | -11% | 25% | 7.7× | 15.0% | +7.7% |